Bora Biologics, a leading contract development and manufacturing organization (CDMO) specializing in biologics, proudly announces its partnership with InvaGen Pharmaceuticals Inc., a wholly owned subsidiary of Cipla Limited, for the manufacture of NYPOZI™ (biosimilar to Neupogen®) at its FDA-registered facility in San Diego, California. This collaboration signifies a major advancement in the biopharmaceutical sector, as […]

Tanvex BioPharma USA (“Tanvex”), a subsidiary of Tanvex BioPharma, Inc. and a contract development and manufacturing organization (CDMO) specializing in biologics under the brand Bora Biologics (“Bora Biologics”), is excited to announce a strategic license and supply agreement with InvaGen Pharmaceuticals, Inc., a wholly owned subsidiary of Cipla Limited in United States (hereinafter referred as […]

Tanvex BioPharma, Inc. (“Tanvex”), a contract development and manufacturing organization (CDMO) for biologics and a biosimilars products company, is pleased to announce the successful completion of its acquisition of Bora Biologics Co., Ltd. (“Bora Biologics”), a subsidiary of Bora Pharmaceuticals. Following this acquisition, Tanvex’s CDMO services will operate under the name Bora Biologics, continuing to […]